Compare Dollar General Corp. (DG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs IDEXX Laboratories, Inc. — how do they compare? Dollar General Corp. trades at $126.54 (market cap $27.42B), while IDEXX Laboratories, Inc. trades at $520.09 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Dollar General Corp. pays a 1.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DG | IDXX | |
|---|---|---|
Market Cap | $27.42B | $40.43B |
Volume | 2,291,517 | 692,164 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $766.68 |
52-Week Low | $95.94 | $504.70 |
Typical Hold Time | 59 Days | 46 Days |
Enterprise Value | $41.60B | $41.32B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $126.16, up 3.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows solid fundamentals with a P/E of 16.14 and ROE of 19.69%, supported by positive cash flow trends and a growing revenue base. Recent news highlights strategic initiatives like tariff refunds, delivery expansion with Instacart, and the DG Media Network, enhancing its value-retail positioning.
The outlook for DG is positive, driven by earnings momentum and analyst consensus pointing to a $137.27 price target. Key opportunities include margin expansion from cost initiatives and digital growth, while risks involve competitive pressures and consumer spending sensitivity. The stock presents a compelling case for value investors seeking steady growth in the discount retail sector.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
